Analyst Creates Bullish Pitch For WAVE Life Sciences, Says It Is 'Leader To Clinic In RNA Editing'
Portfolio Pulse from Vandana Singh
Raymond James has initiated coverage on WAVE Life Sciences Ltd (WVE) with a price target of $9 and an Outperform rating. The analyst believes that WAVE is leading in RNA editing with WVE-006 for Alpha-1 antitrypsin deficiency (AATD), being developed in collaboration with GSK Plc. The collaboration includes a discovery collaboration that allows GSK to advance up to eight programs and Wave to advance up to three programs. WVE shares are up 7.30% at $3.82.
July 05, 2023 | 7:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James has initiated coverage on WAVE Life Sciences with a price target of $9 and an Outperform rating. The company's shares are up 7.30%.
The positive rating and price target from Raymond James, along with the company's leading position in RNA editing, are likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
GSK Plc is collaborating with WAVE Life Sciences on the development of WVE-006 for Alpha-1 antitrypsin deficiency (AATD).
While GSK is involved in the collaboration with WAVE, the news is more focused on WAVE's progress and potential. Therefore, the impact on GSK's stock price is likely to be neutral in the short term.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 60